cyrilzakka/clinical-trials huggingface dataset:
Florida Center for Brain Tumor Research

The purpose of this research study is to collect and store brain tumor tissue samples for future research. The samples will become part of the University of Florida Brain Tumor Tissue Bank/Florida Center for Brain Tumor Research. The goal is to find improved treatments and cures for brain tumors.

The mission of the Florida Center for Brain Tumor Research is to discover cures for brain tumors and develop innovative brain tumor treatment modalities by providing a central repository for brain tumor biopsies and clinical information from individuals throughout the state of Florida, improving brain tumor biomedical research programs within the state of Florida, facilitating funding opportunities, fostering collaboration with brain tumor research organizations and other institutions, and fostering improved technology transfer of brain tumor research findings into clinical trials and widespread public use.

The Florida Center for Brain Tumor Research will collect and store left-over tissue that is not needed for medical care or diagnosis in a tissue bank in the Evelyn F. and William L. McKnight Brain Institute at the University of Florida. Tissue, medical information, cerebrospinal fluid, blood and answers to Quality of Life questionnaires will be stored and made available to researchers. Although developed for Florida, tumor tissue from all other states would be accepted.

Eligibility Criteria:
Inclusion Criteria:

* Children and adults scheduled to undergo brain surgery to remove tumor tissue.
Mobile Phone Radiation and Brain Rhythm in Epileptic Patients

This work is intended to assess the effect of -30 minutes- exposure to mobile-phone on the functions of the central nervous system (CNS) in epileptic patients.

This work shows the effect of the 30 minutes mobile waves' radiation over the normal person brain activity (EEG) and cognition (P300) together with the effect over the unstable brain of the epileptic patients. Exposure to mobile-phone radiation has been reported to increase the spectral power of electroencephalograms (EEGs), particularly in the alpha band, during both the waking and sleeping states. The tendency toward electrical instability of the neural networks of epileptic patients suggests that these individuals may be especially sensitive to electromagnetic fields espcially mobile-phone radiation (MPR). The short-term effects of exposure to electromagnetic (EM) fields on a number of cognitive variables such as memory, attention and speed of decision-making could be assedsed by P 300 latency and amplitude.

Eligibility Criteria:
Inclusion Criteria:

* Both sexes
* Above 18 years
* Epileptic patients (regardless of whether symptomatic, idiopathic, focal or generalized)

Exclusion Criteria:

* Age less than 18 years
* Chronic medical condition
* Epileptic fit in the last 48 hours
Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers


Eligibility Criteria:
Inclusion Criteria:

1. Body mass index ≥18 to ≤33 kg/m2, inclusive.
2. Stable health based on a medical history without any major pathology/surgery in the 6 months

Exclusion Criteria:

1. An uninterpretable or abnormal screening electrocardiogram (ECG) indicating a second- or third-degree atrioventricular block
2. History of risk factors for torsades de pointes, including unexplained syncope, known long QT syndrome, heart failure, myocardial infarction, angina, or clinically significant abnormal laboratory assessments including hypokalemia, hypocalcemia, or hypomagnesemia.
3. A sustained supine systolic blood pressure \>150 mm Hg or \<90 mm Hg or a supine diastolic blood pressure \>95 mm Hg or \<50 mm Hg at Screening or Check-in (Day -1).
Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery

The Primary Objective is to show non inferiority in cardiac safety (i.e myocardial necrosis-MN- assessed by positive cardiac Troponin I -cTnI- ultrasensitive assay) of a Xenon based general anesthesia procedure in patients with elevated cardiac risk scheduled for atherosclerotic vascular surgery (i.e patient with Coronary Arteries Disease risk) when compared to sevoflurane based general anesthesia procedure, postoperatively up to 3 days.

The Primary endpoint is defined as an increase above the 99th percentile of highly sensitive cardiac Troponin I (cTnI) at any time during the 72 h post operatively. Time frame 3 days post-op;

Key secondary endpoint(s) are routine (Local laboratory) dosage of standard cardiac Troponin I (cTnI) at D1 (24h) and D3 (72 h) post operatively, and also in case of any suspicion of Myocardial Infarction , Routine cardiac safety monitoring.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Scheduled for atherosclerotic vascular elective surgery with presumed fast-track,
* Cardiac ischaemic risk supported by:

  * History of myocardial infarction older than 1 month and/or
  * Documented Stable angina (asymptomatic ± medical treatment) and/or
  * History of coronary revascularisation, and/or
  * Surgical Risk Index ("Lee" index) ≥ 3.
  * Written informed consent

Exclusion Criteria:

* Unstable angina within the last 30 days,
* Non controlled arterial Hypertension .
* Severe Cardiac heart Failure (NYHA IV)
* Severe Chronic Obstructive Pulmonary Disease
* Patient already randomized in another ongoing clinical trial
* Patient with recent myocardial infarction (M.I) (less than one month )
* Patient already included in a clinical trial
* History of hypersensitivity to study drugs( i.e Xenon, propofol, sevoflurane, desflurane, isoflurane)
* Malignant hyperthermia
* Documented Elevated intracranial pressure
* Preeclampsia or eclampsia
* Pregnancy and lactation
* Presumed uncooperativeness or legal incapacity
Ramosetron Pre-treatment for PONV and QT Prolongation

Ramosetron is commonly used to prevent postoperative nausea and vomiting (PONV) in the Eastern Asia. The prolongation of QTc interval is a main side effect. In this study, the pre-treatment time of ramosetron to decrease PONV, and QTc prolongation is compared.

This prospective study evaluate 42 female patients who underwent laparoscopic gynecologic surgery under general anesthesia. Group I (n=21) receive 0.6mg of ramosetron at anesthesia induction. Group R (n=21) received the same at the end of surgery. PONV is evaluated at arrival to post-anesthetic care unit (PACU), before induction, discharge from PACU, 24-, 48-, and 72- after discharge from PACU. The QTc interval is checked before anesthesia, at arrival to PACU, and 24-h after discharge from PACU.

Forty two subjects are needed with an α value of 0.05, a power of 0.8, and effect size difference of 0.9.

Eligibility Criteria:
Inclusion Criteria:

* patients who underwent laparoscopic gynecologic surgery

Exclusion Criteria:

* preoperative bradyarrhythmia in ECG
Interactive Telehealth Intervention to Increase Longitudinal Adherence to Repeat Faecal Immunochemical Test Screening

In Hong Kong, Colorectal cancer ranks second in both cancer incidence and mortality. The government-subsidized population-based CRC screening program (the Program) was launched for asymptomatic individuals aged 50-75 years to undergo biennial FIT screenings. A subsidized follow-up colonoscopy is offered to participants with positive FIT results. Participants are advised to repeat the FIT screening 2 years after receiving a negative result. An automated noninteractive short message service (SMS) text reminder, used by the Program as standard care (SC), is delivered to participants who are due for repeat FIT. According to unpublished data, despite SC, only 34% of participants adhere to biennial repeat FIT in the CRC screening program. Nonadherence to repeat FIT screening is caused by forgetfulness and is associated with an individual's psychological health behaviour.

Eligible subject will be randomised to either the TI group or SC group. All subjects will receive an automated SMS text reminder delivered by the Program as the standard care.

Subjects randomized to the TI group will receive the SC as well as an interactive TI with interactive health education messages via a WhatsApp-based chatbot on the repeat FIT due date. All subjects will be followed up on WhatsApp at 3 months after their repeat FIT due date and asked about their repeat FIT status.

Subjects will be invited to participate in four focus group discussions to elucidate how the study intervention influences repeat FIT adherence behaviours, explore the complexity of regular FIT screening, and reveal, based on the participants' accounts, the barriers to and facilitators of their adherence to the repeat FIT screening. The discussion will be audiotaped.

Eligibility Criteria:
Inclusion Criteria:

* 50-75 years old
* already enrolled in the Program with negative FIT results in 2022
* eligible for the Program inclusion and due for repeat FIT screening in 2024
* either the participants themselves or their family members / caregivers have access to and agree to be contacted via WhatsApp
* ability to understand Chinese

Exclusion Criteria:

* who have incomplete conversations with the chatbot, lack of access to WhatsApp, or are unable to provide informed consent will be excluded
Motivational Behavioral and Functional MRI Impairment in Patients With Chronic Neuropathic Pain

The main hypothesis of this study is that the alteration of the reward circuitry underlying the motivational deficit in chronic pain patients compared to healthy subjects results in a decrease in the capacity for reward learning. The fMRI studies have shown that this type of learning depends on the dopaminergic system innervating key regions of the reward system.


Eligibility Criteria:
Inclusion Criteria:

* For cases: patients managed in the neurosurgery department or at CETD for chronic neuropathic pain, of central or peripheral origin.
* For controls: matched to a case on age (±5 years) and sex

Exclusion Criteria:

* Neurodegenerative or inflammatory neurological pathology
* Clinical depressive syndrome
* High doses of opioid treatment (greater than 100 mg/day of morphine equivalent)
* Impaired judgment or inability to receive information that does not allow the performance of behavioral tasks
* Absolute contraindication to MRI (e.g. pacemaker, implantable pacemaker, metallic intra-orbital foreign body)
Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma

Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Ovarian carcinoma is one of most frequent cancer in women worldwide. Epithelial ovarian carcinoma is a group of neoplasms with different histologic pictures. Serous carcinoma is the most common type.

Cancer stem cells (CSCs) can undergo self-renewal and differentiation. EpCAM is a 40-kDa type I transmembrane glycoprotein composed of a large extracellular domain, one transmembrane region, and a small intracellular domain of 26 amino acids. It is abundantly expressed by the majority of human epithelial carcinomas, including colorectal, breast, lung, prostate, ovarian, and endometrial cancers. it is overexpressed in various neoplasms. Recent insights revealed that it is involved in promoting cancer cell proliferation, migration, and invasiveness. It is used as a diagnostic and prognostic marker. EpCAM has also recently been identified as a marker for CSCs.

Eligibility Criteria:
Inclusion Criteria:

* Patients with epithelial ovarian carcinoma and underwent surgery

Exclusion Criteria:

* - Cases received pre-operative chemotherapy or radiotherapy.
* Cases with insufficient clinical data.
Multiple Respiration-Correlated Cone Beam Computed Tomography (CT) Scans to Reduce Target Positioning Errors in Radiotherapy Treatment of Thoracic Cancer

The purpose of this study is to use cone-beam CT scans to more accurately position the tumor during radiation and to see whether this method is more effective than the standard method of using 2D images (portal images), which is a type of X-ray. Cone-beam CT is a type of CT scanner attached to the treatment accelerator that produces 3D images of the patient.

The ability to eliminate the tumor with radiation depends in part on the accuracy of delivering the radiation to the lung. The position of the tumor changes because of normal breathing. Therefore, we want to improve the accuracy of the way the radiation is delivered to the tumor. With cone-beam CT scans taken before and during your treatment, we will be able to determine the location of the tumor with 3D images, measure how much the tumor moves as you breathe, and then position you so that the tumor will get the best delivery of radiation.


Eligibility Criteria:
Inclusion Criteria:

* Patients must have histologic proof of a thoracic malignancy, confirmed at MSKCC and suitable for radiation therapy, in order to be eligible for this study.
* Patients must be older than 18 years of age
* At least part of the tumor must be visible as observed in a diagnostic or planning CT. Patients must have Karnofsky Performance Status ≥ 70%

Exclusion Criteria:

* Pregnant Women
A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care

The primary goal with this study is to document whether patients can maintain their normal bowel microbiota by staying at home compared to those who live at home but are treated in clinic, and those who are treated in the hospital. In addition, the investigators would predict that the quality of life will be higher for those patients treated at the medical home compared to those that stay at the hospital. The investigators also predict that the costs associated with this approach will be significantly lower compared to hospitalized patients. Finally, the investigators propose that the treatment related morbidities and mortality will not be different between the two groups.

Subjects enrolled in the medical home arm and those serving as concurrent controls will have the following studies:

1. Stool collection for analysis at time 0 (prior to preparatory regimen) and then weekly for the first four weeks, at day 60 and 100.
2. The PG-SGA, FACT-BMT and other patient-reported symptom instruments will be collected weekly for the first 4 weeks, at day 60, 100 and patients will be required to complete a daily food diary.
3. Other assessments for toxicities or GVHD will proceed as per current standard of care, for a total blood draw amount of 100 mls from home care subjects and concurrent controls.

Eligibility Criteria:
Inclusion Criteria:

1. Scheduled to undergo a hematopoietic stem cell transplant for any cancer or non-cancer illness from any autologous, related or unrelated donor source including bone marrow, peripheral blood progenitor cell, or umbilical cord blood
2. Age 18-80 years of age
3. Karnofsky Performance Scale (KPS) \> 80
4. A home that is deemed, upon inspection, in suitable condition to serve as a medical home, within a 90-minute driving distance of Duke (home care group only)

Exclusion Criteria:

1. Lack of a caregiver
2. Pregnant women (It is standard of care to assess for pregnancy for all females of child-bearing potential with a serum beta human chorionic gonadotropin (HCG) test within 7 days of starting the preparative regimen prior to transplant. No additional research pregnancy testing will occur.)
3. Patients with a documented active infection prior to starting their preparative regimen. This includes grade 3 or higher viral, bacterial, or fungal infection.
Efficacy of New Protocols in the Treatment of Upper Limb Dysfunctions in Patients With Cerebral Palsy

Immediate and maintaining Efficacy of new protocols in the treatment of upper limb dysfunctions in patients with cerebral palsy.

Cerebral palsy (CP) is the most common childhood motor disability. Spasticity and loss of dexterity are the major problems for motor disability of upper extremity (UE) in patients with CP. This study propose two novel treatment protocols: sensory electrical stimulation (SES) and virtual reality constraint-induced therapy (VRCIT) to improve function of UE in patients with CP. Investigators hypothesize that combined SES and VRCIT treatment have better effect than single therapy (SES or VRCIT).

Eligibility Criteria:
* Inclusion Criteria:

  * Diagnosis with spastic CP with Gross Motor Function Classification System(GMFCS) levels I-IV
  * Aged 2-24 years
  * Ability to undergo clinical assessment
  * Ability to comprehend commands and cooperate during an examination
* Exclusion Criteria:

  * Chromosomal abnormalities
  * Progressive neurological disorder or severe concurrent illness or disease not typically associated with CP
  * Active medical conditions such as pneumonia or poor physical conditions that would interfere with participation
  * Any major surgery or nerve block in the preceding 3 months
  * Metabolic or hormonal disturbance
  * Cardiovascular disorder
  * Poor tolerance or a poor cooperation during assessment
Inhibitory rTMS in Dystonic Wilson Patients

Wilson disease is a genetic disorder resulting in copper accumulation in liver, brain and eye. The neurologic complications include dystonic syndrome, which is a prolonged and excessive muscle activation responsible for abnormal postures. Hand dystonia prevents daily life activities such as writing, which is particularly disabling, since writing is the only mean of communication in these patients with significant slurred speech. Treatment is limited and only partially effective.

Low frequency (\<or=1Hz) repetitive transcranial magnetic stimulation (rTMS) has shown inhibiting properties when applied over the cortex. Since dystonia has been correlated to hyperactivation of the neurons of the somatosensory cortex (SSC), we hypothesize that one single 20-minute session of 1 Hz rTMS applied on left SSC will improve writing of the right dystonic hand, assessed immediately at the end of the session.

This study investigates the handwriting performance of an homogeneous cohort of patients with Wilson disease and right handed dystonia, after one single inhibitory repetitive transcranial magnetic stimulation (rTMS). Fifteen patients with focal right hand dystonia will receive randomly either active or sham rTMS (1 Hz) to the left somatosensory cortex (SSC) in one single 20 minutes session. Handwriting performance will be measured immediately after this unique session (Visual analogic scale of subjective discomfort in writing, DPRE and WCRS scales, pen pressure and pen velocity measured on touchpad), compared to scores obtained 24 hours before the session. Three days later, the patient will receive the other session (sham rTMS or active rTMS) and the same parameters will be evaluated.

This is a single-center, randomized, crossover, prospective, clinical and double-blind study (the rTMS session is performed by the neurophysiologist, but the patient and the neurologist who will perform the handwriting evaluation are blind to the session).

Eligibility Criteria:
Inclusion Criteria:

* Wilson disease with focal right hand dystonia
* No modification of medical treatment for 6 months
* No botulinum toxin administration within the past four months
* Right handed
* Focal right hand dystonia
* Cerebral Magnetic Resonance performed the last 6 months with no other lesion than met in Wilson disease
* Over 18
* Insurance policy holder
* Informed consent

Exclusion Criteria:

* Pregnant woman
* Guardianship procedure
* Seizure history
* Other cerebral lesions on cerebral MRI than met in Wilson Disease
* Unable to stay quiet for 30 minutes
* Handwriting impossible
* Contra-indications to repetitive Transcranial Magnetic Stimulation
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial

Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment

Treatment Group:

Subjects treated with aBMC using the CardiAMP cell therapy system

Sham Control Group:

Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)


Eligibility Criteria:
Inclusion Criteria:

1. Male or female 21 to 80 years of age
2. Canadian Cardiovascular Society (CCS) class III or IV chronic refractory angina.
3. Lack of control of angina symptoms despite maximum tolerated doses of anti-angina drugs.
4. Evidence of inducible myocardial ischemia on baseline stress testing
5. Obstructive coronary disease unsuitable for conventional revascularization
6. Experience angina episodes at a minimum of 7 angina episodes per week (during a 4-week screening period).
7. Able to complete an exercise tolerance test on the treadmill
8. Left ventricular ejection fraction of greater than or equal to 40% as measured by echocardiography.
9. Qualification of a pre-procedure screening of bone-marrow aspiration

Exclusion Criteria

Other cardiac or vascular system or other health-related criteria which may be seen in a patient's history and physical examination.